Research programme: anticancer antibodies - AstraZeneca/Amgen

Drug Profile

Research programme: anticancer antibodies - AstraZeneca/Amgen

Alternative Names: 2.6.1; 3.19.3; AZD5180

Latest Information Update: 05 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; AstraZeneca
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Urokinase plasminogen activator receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Apr 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,,
  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 23 Feb 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top